TEL AVIV (Reuters) - Data from the first ALS patients in a clinical trial treated with BrainStorm Cell Therapeutics adult stem cell therapy did not show significant side effects and the treatment has ...
NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S.
Add Yahoo as a preferred source to see more of our stories on Google. TEL AVIV (Reuters) - Israel-based BrainStorm Cell Therapeutics said on Monday the U.S. Patent and Trademark Office has granted the ...
Our Standards: The Thomson Reuters Trust Principles., opens new tab Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results